Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,209.00 -11.28 (-0.92%)
Official Closing Price Updated: 4:10 PM EDT, Aug 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
IXJ vs. RSPH: Which Healthcare ETF Is the Better Buy? ↗
IXJ offers a higher dividend yield and lower volatility with global exposure, while RSPH's equal-weight approach posted a stronger 1-year return. 
Via The Motley Fool
Topics ETFs
News headline image
1 Unstoppable Vanguard ETF That Could Turn $500 Per Month Into $1 Million ↗
The Vanguard Growth ETF solely focuses on America's largest growth companies. 
Via The Motley Fool
Topics Artificial Intelligence ETFs
News headline image
Novo Nordisk Sues Eli Lilly Over Alleged Deceptive Weight Loss Drug Advertising ↗
Novo Nordisk has filed a lawsuit against Eli Lilly, alleging false advertising and deceptive marketing for Zepbound and Mounjaro treatments. 
Via Benzinga
Topics Lawsuit
Eli Lilly & Co. (NYSE:LLY) Stands Out With High Growth Momentum and a Breakout Setup ↗
Via Chartmill
News headline image
Novo Nordisk's Dividend Story Is Changing -- Here's What Investors Are Missing ↗
Novo Nordisk is offering an attractive 3.5% yield backed by a business where volume is the new focus. 
Via The Motley Fool
News headline image
Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates
EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:CMPS),(NASDAQ:ATAI),(NYSE:JNJ),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Which Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV? ↗
FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approach offers lower costs and steadier performance. 
Via The Motley Fool
Topics ETFs
News headline image
Eli Lilly (LLY): Buy, Sell, or Hold Post Q1 Earnings?
Eli Lilly has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 6.5% to $1,149 p... 
Via StockStory
Topics Stocks
News headline image
Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Merck (NYSE:MRK)
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Now That Eli Lilly Trades Above $1,000, Is a Stock Split Finally on the Table? ↗
Investors have flocked to Eli Lilly for exposure to the high-growth weight loss drug market. 
Via The Motley Fool
News headline image
Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead? ↗
Beam Therapeutics' growing pipeline could reward patient investors. 
Via The Motley Fool
News headline image
For Global Pharma Exposure Is the VanEck Pharmaceutical ETF or iShares Healthcare Fund the Better Buy in 2026? ↗
PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yield beats IXJ by 50 basis points. 
Via The Motley Fool
Topics ETFs
News headline image
Will the Invesco Pharma ETF or iShares Global Healthcare Fund Be the Better Health Care Fund in 2026? ↗
IXJ offers broader diversification with 110 holdings and a lower 0.40% expense ratio, while PJP's concentrated U.S. pharma strategy delivered a 44.90% one-year return. 
Via The Motley Fool
Topics ETFs
News headline image
PJP vs. IYH: Which Healthcare ETF Is the Better Buy? ↗
PJP delivered a higher return over the past year -- but IYH charges lower fees and pays a higher dividend yield. 
Via The Motley Fool
Topics ETFs
News headline image
Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market? ↗
It is definitely a strong contender. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Cathie Wood Is Loading Up on This GLP-1 Stock That Has Soared 1,600% Over the Past 10 Years ↗
Maybe you should, too. 
Via The Motley Fool
News headline image
IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now? ↗
BBH offers concentrated exposure to biotech, while IHE provides higher income with lower volatility by focusing on established drugmakers. 
Via The Motley Fool
Topics ETFs
News headline image
IHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors? ↗
IHE's top two holdings account for over 43% of its portfolio, while IXJ spreads risk across 110 international stocks. Which concentration strategy fits your risk tolerance? 
Via The Motley Fool
Topics ETFs
News headline image
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1 ↗
Viking's latest program seeks to push the envelope in weight loss efficacy. 
Via The Motley Fool
News headline image
IXJ vs. IBBQ: Global Healthcare vs. Biotech -- Which ETF Is the Better Buy? ↗
IBBQ's concentrated biotech play has delivered a higher one-year return, while IXJ'S diversified global healthcare fund has been much less volatile. 
Via The Motley Fool
Topics ETFs
News headline image
The Most Overlooked Reason Eli Lilly Stock Keeps Surging -- and It Has Nothing to Do With Weight Loss ↗
There's a good reason why investors are focused on Eli Lilly's GLP-1 business, but there's more going on at the company. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Wegovy Pill Just Changed the GLP-1 Market. Here's Why Eli Lilly Stock Could Still Win ↗
Novo Nordisk is finally getting one up on its biggest rival. 
Via The Motley Fool
News headline image
Deal Dispatch: Uber Buys Delivery Hero For $14.8 Billion, Eli Lilly Acquires AtaiBeckley, Lulu’s Fashion Considers Strategic Alternatives ↗
Deal Dispatch features companies for sale or bought — also off the block — and what bankruptcies are happening. 
Via Benzinga
News headline image
Why AtaiBeckley Stock Soared Today ↗
The psychedelic drugmaker is being acquired. 
Via The Motley Fool
News headline image
Stock Market Today, July 16: AtaiBeckley Surges on Eli Lilly Acquisition Worth Up To $3.8 Billion ↗
Today, July 16, 2026, the clinical-stage psychedelics developer jumped 33% after Lilly announced a cash deal plus milestone payments. 
Via The Motley Fool
Topics Government Stocks
News headline image
This GLP-1 Stock Could Double by 2030. Here's Why ↗
Investors need to ask tough questions before initiating a position in this biotech company. 
Via The Motley Fool
News headline image
Why Is GH Research Stock Trading Higher on Thursday? ↗
GH Research and Definium Therapeutics stocks rose after Eli Lilly agreed to buy AtaiBeckley in a deal worth up to $3.8 billion. 
Via Benzinga
News headline image
AtaiBeckley Shares Surge as Eli Lilly Seals $3.8B Acquisition Deal ↗
Lilly will acquire AtaiBeckley in a deal worth up to $3.8 billion, adding late-stage depression therapies to its mental health pipeline. 
Via Benzinga
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AtaiBeckley Inc. (Nasdaq – ATAI), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Johnson & Johnson vs. Eli Lilly and: Which Pharma Giant Stock Is a Better Buy in 2026? ↗
One generates steady cash flow with a lower valuation; the other is growing at 45% but carries higher leverage. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.